[Stroke and other thromboembolic complications of atrial fibrillation. Part VII. Prevention of cardioversion related thromboembolism].
In part VII of a series of papers on epidemiology and drug prevention of stroke and other thromboembolic complications of atrial fibrillation the authors analyze data on frequency and contemporary approaches to prevention of thromboembolic complications related to cardioversion. The stress is made on importance of prescription of indirect anticoagulants to all patients with duration of atrial fibrillation exceeding 48 hours. International normalized ratio should be controlled during anticoagulant therapy and be kept between 2.0 and 3.0 at least for 3-4 weeks before and after restoration of sinus rhythm. Absence of atrial thrombi at transesophageal echocardiography does not exclude possibility of thromboembolic complications of cardioversion conducted without anticoagulant therapy.
Preobrazhenskiĭ
D V
DV
Sidorenko
B A
BA
Kiktev
V G
VG
Batyraliev
T A
TA
Pershukov
I V
IV
D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000628:therapy*; D002986:Clinical Trials as Topic; D017548:Echocardiography, Transesophageal; D004554:Electric Countershock / Q000009:adverse effects*; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use; D012189:Retrospective Studies; D013923:Thromboembolism / Q000517:prevention & control*; D013997:Time Factors
D000925:Anticoagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight